Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IW-3718 in Persistent GERD
NCT03561090Phase 3Terminated
- Sponsor
- Ironwood Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of IW-3718 in gastroesophageal reflux disease (GERD), sponsored by Ironwood Pharmaceuticals. Started Jun 2018; status: terminated.
02
Drugs
IW-3718
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03561090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03561090.